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Hepatitis B, hepatitis C, and mortality among
HIV-positive individuals
Alicia C. Thornton, Sophie Jose, Sanjay Bhagani,
David Chadwick, David Dunn, Richard Gilson, Janice Main,
Mark Nelson, Alison Rodger, Chris Taylor, Elaney Youssef,
Clifford Leen, Mark Gompels, Stephen Kegg, Achim Schwenk,
Caroline Sabin, on behalf of the UK Collaborative HIV cohort
(UK CHIC) steering committee
Objectives: To compare rates of all-cause, liver-related, and AIDS-related mortality
among individuals who are HIV-monoinfected with those coinfected with HIV and
hepatitis B (HBV) and/or hepatitis C (HCV) viruses.
Design: An ongoing observational cohort study collating routinely collected clinical
data on HIV-positive individuals attending for care at HIV treatment centres throughout
the United Kingdom.
Methods: Individuals were included if they had been seen for care from 2004 onwards
and had tested for HBV and HCV. Crude mortality rates (all cause, liver related, and
AIDS related) were calculated among HIV-monoinfected individuals and those coin-
fected with HIV, HBV, and/or HCV. Poisson regression was used to adjust for con-
founding factors, identify independent predictors of mortality, and estimate the impact
of hepatitis coinfection on mortality in this cohort.
Results: Among 25486 HIV-positive individuals, with a median follow-up 4.5 years,
HBV coinfection was significantly associated with increased all-cause and liver-related
mortality inmultivariable analyses: adjusted rate ratios (ARR) [95% confidence intervals
(95% CI)] were 1.60 (1.28–2.00) and 10.42 (5.78–18.80), respectively. HCV coinfec-
tion was significantly associated with increased all-cause (ARR 1.43, 95% CI 1.15–
1.76) and liver-related mortality (ARR 6.20, 95% CI 3.31–11.60). Neither HBV nor
HCV coinfection were associatedwith increased AIDS-relatedmortality: ARRs (95%CI)
1.07 (0.63–1.83) and 0.40 (0.20–0.81), respectively.
Conclusion: The increased rate of all-cause and liver-related mortality among
hepatitis-coinfected individuals in this HIV-positive cohort highlights the need
for primary prevention and access to effective hepatitis treatment for HIV-positive
individuals.
Copyright  2017 The Author(s). Published by Wolters Kluwer Health, Inc.
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Introduction
Since the introduction of combination antiretroviral therapy
(cART) for the treatment of HIV infection, rates of AIDS-
related morbidity and mortality have fallen. HIV-positive
individuals who are diagnosed promptly and have good
access to cART are now expected to live a near normal
lifespan. When HIV-positive individuals do die, they are less
likely to die from AIDS-related causes than in the pre or
early cARTera. However, the proportion of people who die
from liver-related causes has increased, with these deaths
largely being related to coinfection with either hepatitis B
virus (HBV) and/or hepatitis C virus (HCV) [1–5].
HIV-positive individuals coinfected with HBV and/or
HCV have higher rates of progression to chronic hepatitis
infection [6–8] and faster progression to fibrosis,
cirrhosis, hepatocellular carcinoma, and end-stage liver
disease [9–12] than individuals with hepatitis infection
alone. Meta-analyses investigating the impact of HBV
and/or HCV coinfection on mortality among HIV-
positive individuals have shown that, overall, coinfection
is associated with increased mortality compared with HIV
alone [13,14]. However, findings from individual studies
are inconsistent, possibly because of variations in
underlying mortality rates in the cohorts studied as well
as differences in treatment and management strategies for
both HIV and hepatitis.
In a number of studies the association between HIV/
HCV coinfection and increased mortality is lost after
adjusting for HIV infection-related parameters (such as
use of cART and CD4þ cell count) [15–18]. This could
suggest that the observed increase in mortality risk is
because coinfected individuals are less likely to initiate
cARTand/or experience a good immunological response
to treatment. Similarly, the association between HIV/
HBV coinfection and increased mortality is often found
to be nonsignificant in multivariable models with similar
mechanisms suggested [19,20]. As most studies that have
examined mortality among coinfected individuals have
reported on all-cause mortality, it is not possible to
examine whether the apparent increase in mortality in
coinfected persons is because of liver disease among
coinfected individuals or because of other causes.
The aims of this study were to compare all-cause, liver-
related, and AIDS-related mortality rates in coinfected
individuals and HIV-monoinfected individuals in a large
HIV-positive cohort in the United Kingdom.
Methods
Data collection and inclusion criteria
The UK Collaborative HIV Cohort (UK CHIC) study is
an observational study collating data from some of the
largest HIV clinics across the United Kingdom; the
dataset used for the present analysis includes data from 11
clinics. Data are collected annually on demographics,
HIV exposure group, HIV treatment, laboratory tests
(CD4þ cell counts and HIV viral loads), and tests
conducted to identify and classify hepatitis coinfection
[21]. Clinics also report information on the date and cause
of death, where recorded in the clinic database. Clinics are
also invited to submit a standardized case report form
(Coding Causing of Death in HIV form) for those
individuals who are known to have died [22].
In September 2012, an expanded data collection process
focussed on individuals from 11 UK CHIC centres who
had evidence of coinfection with HBV [a positive
hepatitis B surface antigen (HBsAg) test result] or HCV (a
positive HCV antibody or positive HCV RNA test
result). This involved detailed review of the clinical HIV
notes of coinfected individuals seen for care from 2004
onwards. This process aimed to verify the hepatitis-
coinfected individuals as well as collect detailed
information on the treatment and outcomes of hepatitis
infection among these individuals. As part of this process,
additional information on the cause of death was
collected for those individuals who were known to
have died.
Individuals were included in this analysis if they had
attended any one of the 11 centres where additional
hepatitis data collection were conducted from 2004
onwards and had ever been tested for HBsAg and
antibody to HCV (anti-HCV) or HCV RNA. Individu-
als were defined as being HBV infected from the date of
their first positive HBsAg test and being HCV infected
from the date of their first positive anti-HCV or HCV
RNA test.
Classifying cause of death
In addition to information on deaths received from
clinics, for deaths prior to 2011, the UK CHIC dataset has
been linked to data from the Office for National Statistics
(ONS) using soundex codes, initials, date of birth, and
sex. From 2011 onwards, the UK CHIC dataset was
linked to mortality data from Public Health England
(PHE). Where these linkages provided additional
information on date and cause of death, the UK CHIC
dataset was updated.
Causes of death were coded as liver related, AIDS related,
or neither. Deaths were coded as liver related where there
was clear evidence that disease in the liver had contributed
to death. This included, for example, decompensated
liver disease, hepatocellular carcinoma and liver failure,
and cancers with liver metastases. Where a nonliver-
related cause of death was recorded but there was
additional mention of viral hepatitis, this was not coded as
a liver-related death. Deaths were coded as AIDS related
either where AIDS was stated as a cause of death or where
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the cause of death included conditions included on the
Centres for Disease Control and Prevention list of AIDS-
defining conditions [23]. Coding was done without
knowledge of an individual’s hepatitis status although
there may have been reference to coinfection within the
information recorded on cause of death. Causes of death
received from each data source were coded separately and
then combined. Where conflicting information was
available, both sources were reviewed to ascertain the
most likely cause of death.
Statistical analysis
Individuals were followed from the latest of their first
HBV or HCV test, entry into UK CHIC, or 1 January
2004. In some cases, individual deaths may be reported to
a clinic a long time after the individual last attended the
clinic. To prevent extended follow-up among these
individuals, an additional 6 months of follow-up was
added to all individuals. Subsequently, all deaths which
occurred within 6 months of the last date that an
individual was seen for care in UK CHIC were included
in the analysis. Where the recorded date of death was
more than 6 months after the last date which they were
seen (15 individuals), follow-up was censored at 6 months
after their last date of follow-up to prevent extended
follow-up among those individuals who die. In addition,
since different centres report data with varying cutoff
dates, all data were censored at 31 December 2011.
Individuals were categorized at baseline as HIV mono-
infected, HIV/HBV coinfected, HIV/HCV coinfected,
or HIV/HBV/HCV triple infected. Individuals moved in
one direction from HIV monoinfected to a coinfection or
triple infection category if there was evidence of a positive
test result during follow-up. The total number of person-
years of follow-up was calculated for each coinfection
category using the date at which an individual entered
that coinfected category and their last date of follow-up
within that category. Mortality rates were calculated as the
total number of deaths divided by the total person-years of
follow-up within each category.
Poisson regression was used to identify predictors of all-
cause, liver-related, and AIDS-related mortality. Fixed
covariates were ethnicity and HIV exposure group as
reported by the clinics. Age, CD4þ cell count, HIV viral
load, cART, and calendar year were updated every 3
months in the analysis. Hepatitis coinfection status was
updated whenever a change occurred. Given the close
relationship between HIV viral load and cART, these two
variables were combined to form a composite covariate
which focussed on whether or not viral load was
detectable and whether or not an individual was receiving
any cART: on cART and viral load less than 50 copies/
ml; on cART and viral load 50–10 000 copies/ml; on
cART and viral load more than 10 000 copies/ml; off
cARTand viral load less than 50 copies/ml; and off cART
and viral load at least 50 copies/ml.
Final models were created using a backwards selection
process to identify those factors that cofounded the effect
of coinfection on mortality and to achieve a parsimonious
model. Final models were adjusted for age, HIVexposure
group, CD4þ cell count, HIV viral load and treatment,
and year of follow-up. Although ethnicity was associated
with mortality in univariable analysis, inclusion of
ethnicity in the final models did not alter the effect of
coinfection on mortality and therefore this was not
included in the final models. Models of all-cause, liver-
related, and AIDS-related mortality were adjusted for the
same confounders to allow for comparison.
HIV-positive IDU have higher mortality rates than HIV-
positive individuals who acquired their HIV infection
through other routes [24–26]. In this cohort there is a
very high prevalence of HCV coinfection among IDU
(83%). Therefore, a sensitivity analysis was conducted
where individuals who had acquired HIV through IDU
were excluded.
Results
Mortality rates
A total of 25 486 individuals contributed 121 814 person-
years of follow-up to the analysis. Median follow-up time
was 4.6 years (interquartile range 2.0, 7.2 years) per
person. Overall, 1065 individuals (4.2%) died during
follow-up. Baseline characteristics of included individuals
are shown in Table 1. The all-cause mortality rate was
8.7/1000 person-years [95% confidence interval (CI)
8.2–9.3]. A total of 95 individuals died of liver-related
causes (a mortality rate of 0.8/1000 person-years, 95% CI
0.6–1.0) and 198 individuals died of AIDS-related causes
(a mortality rate of 1.6/1000 person-years, 95% CI 1.4–
1.9). All-cause and liver-related mortality was higher
among coinfected individuals than among HIV-mono-
infected individuals (Table 2). AIDS-related mortality was
higher among HIV/HBV-coinfected individuals and
among HIV/HBV/HCV triple-infected individuals
compared with HIV-monoinfected individuals but there
was little difference in AIDS-related mortality rates
between HIV-monoinfected and HIV/HCV-coinfected
individuals (Table 2).
Association of hepatitis coinfection with
mortality
All categories of hepatitis coinfection were significantly
associated with an increased risk of all-cause mortality
both in univariable and multivariable analysis (Table 3). In
multivariable analysis the greatest increase in risk of
mortality was seen among individuals who were HIV/
HBV/HCV triple infected. These individuals had a risk
of dying 2.29 times as high as that among HIV-
monoinfected individuals (95% CI 1.62–3.24). The risk
of dying among HIV/HBV and HIV/HCV-coinfected
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individuals was 1.60 (95% CI 1.27–1.99) and 1.42 (1.15–
1.76) times as high as that among HIV-monoinfected
individuals, respectively.
The effect of hepatitis coinfection on the risk of liver-
related mortality was greater than its effect on all-cause
mortality (Table 3). After adjusting for confounders,
compared with the liver-related mortality rate in HIV-
monoinfected individuals, the risk of liver-related
mortality was 10.42 (95% CI 5.78–18.80) times as high
among individuals with HIV/HBV coinfection, 6.20
(95% CI 3.31–11.60) times as high among individuals
with HIV/HCV coinfection, and 15.19 (95% CI 6.94–
33.24) times as high among individuals with HIV/HBV/
HCV triple infection.
Hepatitis coinfection was not associated with an increased
risk of AIDS-related mortality after adjusting for
2528 AIDS 2017, Vol 31 No 18
Table 1. Baseline characteristics of individuals included in the analysis.a
Baseline coinfection status
HIV
monoinfected
HIV/HBV
coinfected
HIV/HCV
coinfected
HIV/HBV/HCV
triple infected
N¼22739 n (%) N¼1216 N (%) N¼1404 N (%) N¼127 N (%) P value
Median age (years; IQR) 37 (31–44) 39 (33–44) 39 (34–44) 37 (33–42) <0.001
Ethnicity
White 13913 (61.1) 625 (51.4) 1148 (81.8) 99 (78.0) <0.001
Black African 5001 (22.0) 368 (30.3) 68 (4.8) 11 (8.7)
Other/unknown 3825 (16.8) 223 (18.3) 188 (13.4) 17 (13.4)
HIV exposure group
MSM 14102 (62.0) 723 (59.5) 602 (42.9) 63 (49.6) <0.001
IDU 172 (24.5) 15 (1.2) 483 (34.4) 33 (26.0)
Male heterosexual 2607 (11.5) 225 (18.7) 105 (7.5) 16 (12.6)
Female heterosexual 4484 (19.7) 190 (15.6) 110 (7.8) 9 (7.1)
Other/unknown 1374 (6.0) 61 (5.0) 104 (7.4) 6 (4.7)
Median CD4þ cell count (cells/ml; IQR) 414 (272–582) 357 (227–540) 388 (243–566) 371 (203–530) <0.001
HIV viral load (copies/ml)
<50 8459 (37.2) 504 (41.5) 550 (39.2) 51 (40.2) 0.004
50 12407 (54.6) 609 (50.1) 768 (54.7) 67 (50.8)
Unknown 1873 (8.2) 103 (8.5) 86 (6.1) 9 (7.1)
cART regimen
NNRTI based 4757 (20.9) 271 (22.3) 250 (17.8) 22 (17.3) <0.001
PI based 2409 (10.6) 136 (11.2) 189 (13.5) 18 (14.2)
Other regimen 2847 (12.5) 235 (19.3) 224 (16.0) 25 (20.0)
Not on ART 12726 (56.0) 574 (47.2) 741 (52.8) 62 (48.8)
Year of entry into UK CHIC
1996–1999 7341 (32.3) 493 (40.5) 615 (43.8) 55 (43.3) <0.001
2000–2004 6072 (26.7) 309 (25.4) 327 (23.3) 23 (18.1)
2005–2009 7196 (31.7) 322 (26.5) 378 (26.9) 37 (29.1)
2010 2130 (9.4) 92 (7.6) 84 (6.0) 12 (9.5)
Died during follow-up
Yes 816 (3.6) 87 (7.2) 145 (10.3) 17 (13.4) <0.001
No 21923 (96.4) 1129 (92.9) 1259 (89.7) 110 (86.6)
aIQR, interquartile range; cART, combination antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor;
UK CHIC, UK collaborative HIV cohort study.
Table 2. All-cause, liver-related, and AIDS-related mortality, 2004–2012, by hepatitis infection status.
HIV/hepatitis
infection
Number
of individuals
Person-years
follow-up
All-cause mortality Liver-related mortality AIDS-related mortality
Number
of deaths
Mortality
ratea (95% CI)
Number
of deaths
Mortality
ratea (95% CI)
Number
of deaths
Mortality
ratea (95% CI)
HIV 22739 103057 761 7.4 (6.9–7.9) 27 0.3 (0.2–0.4) 164 1.6 (1.4–1.9)
HIV/HBV 1427 6933 96 13.8 (11.2–16.9) 24 3.5 (2.2–5.2) 15 2.2 (1.2–3.6)
HIV/HCV 2325 10180 172 16.9 (14.5–19.6) 34 3.3 (2.3–4.7) 13 1.3 (0.7–2.2)
HIV/HBV/HCV 435 1644 36 21.9 (15.3–30.3) 10 6.1 (2.9–11.2) 6 3.6 (1.3–7.9)
Total 25486 121814 1065 8.7 (8.2–9.3) 95 0.8 (0.6–1.0) 198 1.6 (1.4–1.9)
CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.
aMortality rates per 1000 person-years of follow-up.
confounding factors (Table 3). Compared with HIV-
monoinfected individuals, there was no significant
difference in the risk of AIDS-related mortality among
HIV/HBV-coinfected individuals [adjusted rate ratios
(ARR) 1.07, 95% CI 0.63–1.83] or among HIV/HBV/
HCV triple-infected individuals (ARR 1.55, 95% CI
0.65–3.70). However, HIV/HCV-coinfected individuals
had a significantly lower risk of AIDS-related mortality
than HIV-monoinfected individuals (ARR 0.40, 95% CI
0.19–0.81).
Some other associations were also observed. In all models,
having acquired HIV infection through IDU was a strong
predictor of mortality. In addition, increasing age, lower
CD4þ cell counts, and having a high HIV viral load while
being on cARTwere associated with increased mortality
(data not shown).
Sensitivity analyses
When individuals who acquired their HIV through IDU
were excluded from the models of all-cause mortality and
liver-related mortality, there were no changes to the
direction of the associations between hepatitis coinfection
and increased mortality. The effect sizes also remained
similar (data not shown). When IDU were excluded from
the model of AIDS-related mortality, the association
between HIV/HCV coinfection and decreased risk of
liver-related mortality became nonsignificant (ARR
0.46, 95% CI 0.19–1.13); however, the direction of
the effect remained the same.
Discussion
In the UK CHIC study, among patients under follow-up
in an era of effective treatment for HIV infection,
coinfection with HBV or HCV was significantly
associated with increased all-cause mortality even after
adjusting for other known predictors of mortality. The
association between liver-related mortality and coinfec-
tion was even more striking. In contrast, HIV/HBV
coinfection and HIV/HBV/HCV triple infection was
not associated with AIDS-related mortality.
There was some evidence of a protective effect of HCV
on the risk of AIDS-related mortality. IDU usually
acquire HCV very soon after they start injecting drugs
and, therefore, are likely to have been infected with HCV
for longer than individuals who have acquired their
infections through other routes. IDU also have higher
rates of other causes of mortality than individuals who do
not inject drugs. Therefore, the protective effect of HCV
infection with regard to AIDS-related mortality when
IDU are included in the model may be because of long-
standing HCV infection, or other mortality specifically
associated with injecting behaviours, acting as competing
risks for AIDS-related mortality. After excluding IDU
from the analysis the effect became nonsignificant;
however, the effect size remained the same. It is possible
that this is an effect of the recent outbreaks of acute HCV
among MSM. These men are likely to be well engaged
with HIV care and are therefore less likely to experience
AIDS events.
The association of HIV/HBV coinfection with increased
all-cause mortality and the even larger effect of HBV
infection on the risk of liver-related mortality has been seen
in other cohorts [12,14,20,27–29]. This analysis indicates
that HIV/HBV-coinfected individuals are 1.6 times more
likely to die than HIV-monoinfected individuals. In the
largest previously published study comparing mortality
among HIV/HBV coinfected and HIV-monoinfected
individuals, individuals from the EuroSida cohort who
were HIV/HBV coinfected were 1.54 times as likely to die
than HIV-monoinfected individuals [27]. The magnitude of
increased risk of liver-related mortality among HIV/HBV-
coinfected individuals compared with HIV-monoinfected
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Table 3. Results from adjusted and unadjusted Poisson regression assess the association of HIV/hepatitis co with all-cause, liver-related, and
AIDS-related mortality.
Outcome Hepatitis coinfection
Unadjusted Adjusteda
Risk ratio (95% CI) P value Risk ratio (95% CI) P value
All-cause mortality HIV monoinfected 1 – 1 –
HIV/HBV coinfected 1.88 (1.52–2.32) <0.0001 1.60 (1.28–2.00) <0.0001
HIV/HCV coinfected 2.29 (1.94–2.70) <0.0001 1.42 (1.15–1.76) <0.0001
HIV/HBV/HCV triple infected 2.97 (2.12–4.14) <0.0001 2.29 (1.62–3.24) <0.0001
Liver-related mortality HIV monoinfected 1 – 1 –
HIV/HBV coinfected 13.21 (7.62–22.90) <0.0001 10.42 (5.78–18.80) <0.0001
HIV/HCV coinfected 12.74 (7.69–21.12) <0.0001 6.20 (3.31–11.60) <0.0001
HIV/HBV/HCV triple infected 23.22 (11.24–47.98) <0.0001 15.19 (6.94–33.24) <0.0001
AIDS-related mortality HIV monoinfected 1 – 1 –
HIV/HBV coinfected 1.36 (0.80–2.30) 0.25 1.07 (0.63–1.83) 0.80
HIV/HCV coinfected 0.80 (0.46–1.41) 0.44 0.40 (0.20–0.81) 0.01
HIV/HBV/HCV triple infected 2.29 (1.02–5.18) 0.05 1.55 (0.65–3.70) 0.32
CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.
aAll models were adjusted for age, HIV exposure group, CD4þ cell count, HIV viral load and treatment, and year of follow-up.
individuals in this UK cohort (10.4 times higher) is greater
than previously reported. For example, in the EuroSida
study the risk of liver-related mortality among HIV/HBV-
coinfected individuals was 3.3 times as high as that among
HIV-monoinfected individuals [27]. Similarly, in another
large collaborative study (D:A:D) the risk of liver-related
mortality was 3.7 times as high in HIV/HBV coinfected
compared with HIV-monoinfected individuals. The
difference in effect size between the present and previous
studies may be because of different levels of liver-related
mortality in the monoinfected individuals in each cohort.
As UK CHIC has lower proportions of IDU than other
cohorts, the rate of liver deaths in the monoinfected group
is likely to be lower within UK CHIC, and therefore the
additional risk of liver-related mortality among the
coinfected group will be greater. Finally, the finding that
HIV/HBV coinfection is strongly associated with liver-
related mortality but not with AIDS-related mortality is in
line with research which has shown that, in the cARTera,
HBV coinfection is not associated with an increased
progression of HIV to AIDS [14,19,27].
The association between increased mortality and HIV/
HCV coinfection has also been shown in other cohorts
[29–39]. In the present analysis, the risk of all-cause
mortality was 1.4 times as high among HIV/HCV-
coinfected individuals than that in HIV-monoinfected
individuals. This is similar to the effect size seen in a
meta-analysis of 20 studies comparing mortality in HIV/
HCV coinfected to that in HIV-monoinfected individ-
uals in which HIV/HCV-coinfected individuals had a
risk of mortality which was 1.35 times as high as that in
HIV-monoinfected individuals [13]. The current study
showed a 6.2 times increased risk of liver-related death
for HIV/HCV-coinfected individuals compared with
HIV-monoinfected individuals. This magnitude of
increased risk was smaller than that seen in other
cohorts. For example, in the EuroSida cohort the risk of
liver-related mortality was 11.7 times higher among
HIV/HCV-coinfected individuals than among HIV-
monoinfected individuals. This is possibly as a result of
the higher proportion of IDU in other cohorts compared
with in UK CHIC. As with HIV/HBV coinfection,
HIV/HCV coinfection was not associated with AIDS-
related mortality. This supports the hypothesis that HIV/
HCV coinfection does not alter progression of HIV to
AIDS in the era of HAART [37,40].
In assessing the association of hepatitis coinfection with
mortality, some other associations were also observed. As
expected, IDU and older age and lower CD4þ cell count
were all significantly associated with increased all-cause,
liver-related, and AIDS-related mortality. The observed
association between all-cause, liver-related, and AIDS-
related mortality and cART/viral load is less intuitive.
Being on cARTand having a high HIV viral load may be a
sign of treatment failure. Alternatively, these could be
individuals who have become very unwell from liver
disease and have, therefore, opted to stop taking cART. In
each of these cases, individuals could be expected to very
unwell compared with individuals in the other HIV
treatment/viral load categories which might explain the
increased risk of mortality.
The study has some limitations. First, although the
linkages of the UK CHIC dataset and data from ONS and
PHE have resulted in very reliable data on the number of
individuals who have died, accurately establishing cause of
death is difficult. Therefore, it is possible that the number
of AIDS-related and liver-related deaths are under-
estimated as cause of death data remains incomplete. In
addition, data within UK CHIC are obtained from HIV
clinics which may be more likely to have a record of a
death related directly to HIV (including AIDS-related
death) than death from other causes (including liver-
related death). However, it is hoped that the use of three
sources of death data (UK CHIC, coding causing of death
in HIV forms, and PHE/ONS data) have limited
introduction of any bias because of differential reporting
of deaths within HIV clinics.
Conversely, it is also possible that the number of liver-related
deaths is overestimated in coinfected individuals as a known
hepatitis diagnosis may influence how a death is reported. In
this analysis, the impact of this was minimized by not coding
a death as liver related purely on the basis of a mention of
viral hepatitis infection and by coding the deaths without
knowledge of the individual’s hepatitis status.
Efforts to improve the reporting of deaths in UK CHIC
have intensified in more recent years. In particular, linkage
to PHE data were first conducted using a dataset that
contained data up to the end of 2010. Therefore, it is likely
that from 2010 onwards a higher proportion of individuals
who had died would have information recorded in UK
CHIC. This may have introduced some bias with increased
deaths having been reported in more recent years.
Although every effort has been made in the analyses
presented to adjust for potential confounding factors, there
may be some residual confounding. Information on drug
use was only available if IDU was the individual’s probable
route of HIVexposure. Drug use (including non-IDU) is
associated with hepatitis coinfection [41,42] and may also
increase the risk of death. Similarly, there is no data within
UK CHIC on alcohol use. Alcohol use may be higher
among coinfected groups than others and is also associated
with an increased risk of liver disease and liver-related
mortality. Biochemical markers of cirrhosis were not
included in the analysis are we believe cirrhosis to be on the
causal pathway from hepatitis infection to mortality.
Hepatitis D virus (HDV) is associated with an increased
risk of mortality among HIV/HBV-coinfected individu-
als [43]. The HDV status of HIV/HBV-coinfected
individuals was unknown, therefore, we were not able
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to assess the impact of HDV on mortality among this
cohort and the result presented may not represent the
effect of HBV infection alone on mortality among HIV-
positive individuals. Data on HCV RNA within the
dataset were limited and therefore it was not possible to
assess the effect of clearance of HCV on mortality in this
analysis or to limit the analysis to individuals who have
active HCV infection. Similarly, it was not possible to
assess the effect of treatment with tenofovir on mortality
among HBV-coinfected individuals. Median follow-up
for individuals in this study was less than 5 years. This
could be considered as a relatively short follow-up when
assessing mortality, despite this an association between
coinfection and mortality was still observed. Finally, using
the data from UK CHIC it is not possible to determine
the date of infection with HBV or HCV as individuals
may have been infected for some time before their first
positive result in the dataset. Therefore, it is not possible
to examine the effect of timing of hepatitis infection
compared to HIV infection on the clinical outcomes.
Despite these limitations, the analyses presented utilized a
large cohort of HIV-positive individuals and, as such,
provide estimates of mortality among HIV and hepatitis-
coinfected individuals in the United Kingdom. Directly
acting agents for treatment of HCV infection are now
availablewhichhave high rates of cure. If patients are able to
access these treatments the increased risk of mortality from
HCV infection may be mitigated. The findings of this
study highlight the need for primary prevention strategies
and the importance of ensuring prompt diagnosis of
hepatitis coinfection among HIV-positive individuals and
effective linking of coinfected individuals to treatment and
monitoring to limit the progression of liver disease.
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